Why Deciphera Pharmaceuticals’ tirabrutinib NDA matters for the future of CNS lymphoma therapy
FDA accepts tirabrutinib NDA for relapsed or refractory PCNSL. Find out what this means for CNS lymphoma treatment and regulatory strategy.
What the Invenra B-Body licensing deal changes for Twist Bioscience and antibody discovery services
Twist Bioscience licenses Invenra’s bispecific antibody platform. Find out how this reshapes biologics discovery infrastructure and industry dynamics.
Why Janux Therapeutics’ JANX011 trial could redefine immune reset in autoimmune disease
Janux Therapeutics begins first human study of JANX011. Find out how CD19 immune reset could change autoimmune treatment strategies.
Moleculin Biotech, Inc. secures Japanese IP boost as Annamycin enters pivotal Phase 3
Moleculin secures Japanese patent for Annamycin reconstitution. Discover what this means for AML development and global market strategy.
FDA IND clearance propels ViroMissile’s IDOV-Immune into major U.S. cancer centers
ViroMissile expands its IDOV-Immune Phase I trial to U.S. sites after FDA IND clearance. Discover what this means for systemic oncolytic therapy.
Novo Nordisk secures EU nod for higher Wegovy dose amid intensifying GLP-1 competition
EU approves 7.2 mg Wegovy for obesity. Explore what this means for efficacy, competition and reimbursement across Europe.
Biofrontera targets U.S. label expansion for Ameluz in trunk and extremities
Phase 1 PK data bring Ameluz closer to broader FDA review. Explore the regulatory stakes and market impact in actinic keratosis.
Can Dialed Moods make biohacking sustainable beyond niche wellness communities
Dialed Moods expands its biohacking strategy with plant-based supplements. Explore what this shift means for the future of consumer wellness.
Why Newron’s EUR 38m financing matters for Phase III evenamide development in treatment-resistant schizophrenia
Newron Pharmaceuticals secures up to EUR 38 million to advance evenamide Phase III trials. Find out what this means for treatment-resistant schizophrenia.
Why Compass Pathways’ upcoming COMP360 data could redefine late-stage psychedelic drug development
Compass Pathways is set to release pivotal Phase 3 COMP360 data in treatment-resistant depression. Find out why this readout could reshape psychedelic drug development.